Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data

To date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, with little real-world evidence on overall survival (OS), clinical trial enrollment or end-of-life quality of care. Cost consequenc...

Full description

Saved in:
Bibliographic Details
Published in:EClinicalMedicine 2024-03, Vol.69, p.102443-102443, Article 102443
Main Authors: Hernando-Calvo, Alberto, Nguyen, Paul, Bedard, Philippe L., Chan, Kelvin K.W., Saleh, Ramy R., Weymann, Deirdre, Yu, Celeste, Amir, Eitan, Regier, Dean A., Gyawali, Bishal, Kain, Danielle, Wilson, Brooke, Earle, Craig C., Mittmann, Nicole, Abdul Razak, Albiruni R., Isaranuwatchai, Wanrudee, Sabatini, Peter, Spreafico, Anna, Stockley, Tracy L., Pugh, Trevor J., Williams, Christine, Siu, Lillian L., Hanna, Timothy P.
Format: Article
Language:English
Subjects:
Cost-consequence analysis
Matched therapies
Molecular profiling
NGS
Precision oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, with little real-world evidence on overall survival (OS), clinical trial enrollment or end-of-life quality of care. Cost consequence analysis of NGS testing (555 or 161-gene panels) for advanced solid tumors through the OCTANE clinical trial (NCT02906943). This is a longitudinal, propensity score-matched retrospective cohort study in Ontario, Canada using linked administrative data. Patients enrolled in OCTANE at Princess Margaret Cancer Centre from August 2016 until March 2019 were matched with contemporary patients without large gene panel testing from across Ontario not enrolled in OCTANE. Patients were matched according to 19 patient, disease and treatment variables. Full 2-year follow-up data was available. Sensitivity analyses considered alternative matched cohorts. Main Outcomes were mean per capita costs (2019 Canadian dollars) from a public payer's perspective, OS, clinical trial enrollment and end-of-life quality metrics. There were 782 OCTANE patients with 782 matched controls. Variables were balanced after matching (standardized difference  0.40), and greater in two (ovary, biliary, both p 
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2024.102443